Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 24, 2018HaemophiliaOpen Access

Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

HHH.C.A.M. HazendonkErasmus MCJHJessica M. HeijdraErasmus MCNJNico C. B. de JagerAmsterdam UMC Location University of Amsterdam

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hazendonk et al. (2018) studied this question.

synapsesocial.com/papers/6a945f6c81fc78f010707cedhttps://doi.org/10.1111/hae.13451
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment of von Willebrand disease with FVIII/VWF concentrates.2011 · 27 citations
  2. 2Surgery in patients with von Willebrand disease2016 · 26 citations
  3. 3Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease2002 · 120 citations
  4. 4A comparative <i>in vitro</i> evaluation of six von Willebrand factor concentrates2004 · 64 citations
  5. 5Nordic Haemophilia Council's Practical Guidelines on Diagnosis and Management of v on Willebrand Disease2011 · 26 citations